No Data
No Data
Innocare (09969) innovative drug ICP-332 completed the first dose administration in the United States.
Innocare (09969) announced that the company recently learned that its innovative drug ICP-332 has completed... in the USA.
Innocare (688428.SH): ICP-332 completes its first dose to participants in the United States.
On July 24th, Gelunhui reported that Innocare (688428.SH) recently learned that its innovative drug ICP-332 has completed the first dosing of subjects in the United States. ICP-332 is a Class 1 innovative drug with global intellectual property rights independently developed by the company. It is an efficient and highly selective new oral inhibitor of TYK2. TYK2 is a non-receptor tyrosine kinase belonging to the Janus kinase (JAK) family and plays an important role in the pathogenesis of T cell inflammation.
Express News | InnoCare Announces First Subject Dosed in Clinical Trial of Tyk2 Inhibitor Icp-332 in the U.S.
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
Innocare issued a total of 1.635 million RMB shares.
In July 18, 2024, innocare (09969) announced that it has issued a total of 1.635 million RMB shares to two directors and 86 incentive recipients for the first vesting period of the 2023 STAR Restricted Stock Award Plan.
Innocare (09969) issued a total of 1.635 million RMB shares.
Innocare (09969) announced that on July 18, 2024, it will implement the 2023 Star Market restrictive measures...
No Data